Rituxan (rituximab) - Roche
Cablivi (caplacizumab-yhdp) - Sanofi
Refractory Acquired Thrombotic Thrombocytopenic Purpura in the Third Trimester of Twin Pregnancy: A Case Report. (PubMed, Int Med Case Rep J) - Oct 5, 2026 - "Rapid ADAMTS13 testing, timely delivery, and combined plasma exchange with rituximab and caplacizumab enabled full recovery in this refractory twin-pregnancy case. Multidisciplinary care is critical to differentiate from obstetric mimics and achieve favorable outcomes." 
Journal • Allergy • Cardiovascular • Fatigue • Gynecology • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Musculoskeletal Pain • Obstetrics • Pain • Pulmonary Disease • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis
http://www.ncbi.nlm.nih.gov/pubmed/42829733
 
Herbert Kayiga; Jeya Sushimitha Jawahar Kanth; Micheal Collins Segawa; Morrish Obol Okello; Sheethal Madari; Thuparambil M Ravi Anish
 
Oct 5, 2026
 
Prev Next